Neurologic Impairment by Opioids
Conditions
Brief summary
The investigators aim to prove the feasibility of a non-invasive means to identify temporary neurological impairment resulting from the use of a commonly prescribed opioid by identifying an oculomotor biosignature associated with temporary neurologic impairment in pain-free opioid-naïve subjects, and to initiate the development of such a signature. The investigators also sought to establish the presence of a dose-dependent biosignature for opioid impairment.
Detailed description
To determine the detrimental effects of opioid intoxication on normal oculomotor function, the investigators will collect data from up to 25 subjects before and during oxycodone induced intoxication. A within-subjects design will be used, and subjects will be tested under conditions of no dose (placebo), low dose, and high dose. Subjects will be tested during 3 sessions (baseline, placebo, oxycodone); separated by 7 days to allow for complete washout of any drug that was administered. Subjects will perform tests of visual fixation, saccade speed and saccade accuracy, cognitive control over saccades, cognitive control over visual scanning, and visual pursuit. Eye movement data will be collected using an SR Research EyeLink 1000 Plus eye tracking system. Analysis of the data will be performed by comparing each subject state against the baseline measurements, where baseline represents an unimpaired subject state. Based on prior work with marijuana intoxication, the investigators expect that this data and analysis will successfully reveal a constellation of oculomotor dynamics that can be used to classify whether an individual is or is not currently impaired by oxycodone. Based on published studies, the investigators anticipate these changes will generalize across the opioid class, creating a biosignature of opioid impairment.
Interventions
DRUGOxycodone
Oxycodone in 5mg increments up to a maximum of 10mg
Sponsors
Zxerex Corporation
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
21 Years to 59 Years
Healthy volunteers
Yes
Inclusion criteria
* Adults between 21 and 59 years of age. * Males and females; women must practice an effective form of birth control (condoms, diaphragm, birth control pill, IUD).
Exclusion criteria
* Prior use of any opioids during the preceding 30 days. * Positive urine drug test for any drug at any point during the study. * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Eye movement velocity | 1 hour post-dose for 3 hours across 3 sessions, minimum 48 hours between sessions. | Eye position over time is recorded and tracked using a specialized eye-tracking camera system during a battery of visual tests under control and oxycodone challenge conditions. This data is converted to a velocity measure as millimeters per second (mm/second) and then converted to an angular velocity as degrees of visual angle per second (dva/second). |
| Pupil area change | 1 hour post-dose for 3 hours across 3 sessions, minimum 48 hours between sessions. | Changes in pupil area are recorded over time using specialized a eye-tracking camera system. Screen illumination is abruptly changed from dark to maximum brightness and back while the pupils size is measured. The pupil area is represented in the units millimeters squared (mm\^2). |
Countries
United States
Outcome results
None listed